文献速递结核与非结核分枝杆菌艾滋病与性传播感染

南非耐多药结核病与人类免疫缺陷病毒共感染患者接受同期治疗后的生存率与治愈率提高

Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该前瞻性观察性研究于2011至2013年在南非纳入206例培养确诊的耐多药结核病患者,其中150例合并HIV感染,所有参与者接受标准化耐多药结核病和HIV方案并每月随访。结果显示合并HIV感染与未感染者的生存率分别为86%和94%(P=.34),无显著差异;191例有最终结局者中130例(73%)治愈或完成治疗,不因HIV状态而异(P=.50)。CD4计数≤100个/mm3是死亡最强危险因素(校正风险比15.6,95%CI 4.4-55.6)。

要点

  • 合并HIV感染的耐多药结核病患者接受同期抗逆转录病毒治疗,2年生存率86%,与未感染者的94%无显著差异(P=.34)。
  • 191例有最终结局者中130例(73%)治愈或完成治疗,治愈率不因HIV状态而异(P=.50)。
  • CD4计数≤100个/mm3是死亡最强危险因素,校正风险比15.6(95%CI 4.4-55.6)。

核心结论

  • 接受同期抗逆转录病毒治疗的耐多药结核病合并HIV感染患者,其生存率和治疗结局接近未感染HIV的患者。
  • HIV感染者中CD4计数≤100个/mm3者死亡风险最高。
  • 这些发现为耐多药结核病与HIV同期治疗提供了关键证据。

研究设计与样本

  • 前瞻性观察性研究,2011至2013年在南非纳入培养确诊的耐多药结核病患者,包括合并与不合并HIV感染者。
  • 共纳入206例参与者,其中150例HIV感染,131例(64%)为女性,中位年龄33岁(四分位距26-41)。
  • 参与者接受标准化耐多药结核病和HIV方案,每月随访治疗反应、不良事件和依从性。

主要发现

  • 191例有最终耐多药结核病结局的参与者中,130例(73%)治愈或完成治疗,治愈率不因HIV状态而异(P=.50)。
  • 2年后CD4计数中位增加140个/mm3(P=.005),64%的HIV感染者病毒载量检测不到。
  • HIV感染者和未感染者生存率分别为86%和94%(P=.34)。
  • 死亡最强危险因素为CD4计数≤100个/mm3(校正风险比15.6,95%CI 4.4-55.6)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mortality in multidrug-resistant (MDR) tuberculosis-human immunodeficiency virus (HIV) coinfection has historically been high, but most studies predated the availability of antiretroviral therapy (ART). We prospectively compared survival and treatment outcomes in MDR tuberculosis-HIV-coinfected patients on ART to those in patients with MDR tuberculosis alone. METHODS: This observational study enrolled culture-confirmed MDR tuberculosis patients with and without HIV in South Africa between 2011 and 2013. Participants received standardized MDR tuberculosis and HIV regimens and were followed monthly for treatment response, adverse events, and adherence. The primary outcome was survival. RESULTS: Among 206 participants, 150 were HIV infected, 131 (64%) were female, and the median age was 33 years (interquartile range [IQR], 26-41). Of the 191 participants with a final MDR tuberculosis outcome, 130 (73%) were cured or completed treatment, which did not differ by HIV status (P = .50). After 2 years, CD4 count increased a median of 140 cells/mm3 (P = .005), and 64% had an undetectable HIV viral load. HIV-infected and HIV-uninfected participants had high rates of survival (86% and 94%, respectively; P = .34). The strongest risk factor for mortality was having a CD4 count ≤100 cells/mm3 (adjusted hazards ratio, 15.6; 95% confidence interval, 4.4-55.6). CONCLUSIONS: Survival and treatment outcomes among MDR tuberculosis-HIV individuals receiving concurrent ART approached those of HIV-uninfected patients. The greatest risk of death was among HIV-infected individuals with CD4 counts ≤100 cells/mm3. These findings provide critical evidence to support concurrent treatment of MDR tuberculosis and HIV.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Brust JCM, Shah NS, Mlisana K, et al. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa. Clin Infect Dis. 2018. PMID: 29293906. doi:10.1093/cid/cix1125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。